ProductsAbout UsContact Us
Chromium Plus™
Chromium Plus™

High strength chromium with important co-factors including vanadium & alpha lipoic acid

   60 VCAPS® (vegetable capsules)*#

Chromium Plus™ contains a unique form of chromium polynicotinate, along with alpha lipoic acid, inositol & vanadium to assist healthy blood sugar metabolism.

 


Practitioner Information

  • Chromium is an essential nutrient that plays an important role in glucose metabolism by enhancing the effects of insulin.[1] Evidence suggests that chromium supplementation may alleviate symptoms associated with insulin resistance, such as high blood glucose and lipid abnormalities.[2]
  • Chromium has been shown to be beneficial in assisting varying degrees of glucose intolerance.[3],[4]
  • Chromium Plus™ features chromium polynicotinate, a niacin-bound chromium. This form demonstrates high bioavailability and effectiveness.[5] Toxicity has not been reported.[6]
  • Chromium polynicotinate has been shown to support healthy weight loss in women.[7],[8]
  • Prior to the discovery of insulin in 1922, vanadium was used for the control of blood sugar.[9] Vanadium acts by assisting enhanced insulin effectiveness in individuals with reduced insulin sensitivity.[10],[11],[12],[13]
  • Alpha lipoic acid (ALA) supports carbohydrate metabolism and may help prevent common diabetic complications, including protein glycosylation.[14] ,[15],[16],[17],[18],[19]
  • ALA is considered a potent antioxidant. Oxidative stress plays a central role in diabetic complications. ALA may help reduce oxidative stress in the pancreas.[14]
  • Scientific research also supports ALA benefits in heavy metal clearance.[14]
  • Zinc is an important mineral that plays a role in the synthesis and action of insulin.[20] The human body does not produce zinc on its own, so it must be obtained from outside sources.[20] This is particularly important in individuals who may be zinc deficient.[20],[21]
  • Inositol is required for normal nerve function. Neuropathy is a condition that has been reported to improve with inositol supplementation.[22]

Each Vcap® Contains


Chromium polynicotinate                                2000µg

              Equiv. to chromium                            250µg

Alpha lipoic acid                                             200mg

Inositol   100mg

Zinc glycinate                                                  53mg

Equiv. to zinc                                       15mg

Vanadium aminoate                                        100mg

Equiv. to vanadium                                 1mg

 

Contains no gluten, soy, dairy, yeast, wheat, animal products, artificial flavours, colours or preservatives.

Directions For Use


Adults: Take 1-3 capsules a day.

 

Warnings

  • Chromium Plus™ should not be taken in pregnancy or lactation.
  • Vanadium has not been studied in pregnancy or lactation.

Precautions & Considerations

  • Monitoring of individuals taking prescribed diabetic medication is recommended.

References

[1] Lukaski HC. Chromium as a supplement. Annu Rev Nutr. 1999;19:279-302.

 

[2] Chen G, Liu P, Pattar GR, et al. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol. 2006;20(4):857-870.

 

[3] Anderson, RA. Chromium, glucose intolerance and diabetes. 1998 Dec;17(6):548-55.

 

[4] Anderson RA, Polansky MM, Bryden NA, Canary JJ. Supplemental-chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low-chromium diets. Am J Clin Nutr. 1991;54:909–16.

 

[5] Lamson DS, Plaza SM. The safety and efficacy of high-dose chromium. Altern Med Rev. 2002 Jun;7(3):218-35.

 

[6] Bagchi D, Stohs SJ, Downs BW, et al. Cytotoxicity and oxidative mechanisms of different forms of chromium. Toxicology 2002 Oct 30;180 (1):5-22.

 

[7] Crawford V, Scheckenbach R, Preuss HG. Effects of niacin-bound chromium supplementation on body composition in overweight African-American women. Diabetes Obes Metab. 1999 Nov;1(6):331-7.

 

[8] Grant KE, Chandler RM, Castle AL, et al. Chromium and exercise training: effect on obese women. Med Science Sports Exer. 1997 Aug;29(8):992-8.

 

[9] Dey L, Attele AS, Yuan CS. Alternative therapies for type 2 diabetes. Altern Med Rev. 2002 Feb;7(1):45-58.

 

[10] Cohen N, Halberstam M, Shlimovich P, et al. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1995;95:2501-2509.

 

[11] Halberstam M, Cohen N, Shlimovich P, et al. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 1996;45:659-666.

 

[12] Badmaev, V., Prakash, L. and Majeed, M. (1999) Vanadium: A Review of its Potential Role in the Fight against Diabetes. The Journal of Alternative and Complementary Medicine, 5(3):273-291.

 

[13] Mukherjee B, Patra B, Mahapatra S, et al. Vanadium--an element of atypical biological significance. Toxicol Lett. 2004 Apr 21;150(2):135-43.

 

[14] No authors listed. Alpha-lipoic acid. Monograph. Altern Med Rev. 2006 Sep;11(3):232-7.

 

[15] Konrad T, Vicini P, Kusterer K, et al. alpha lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care. 1999;22:280–7.

 

[16] Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care. 1997;20:369–73.

 

[17] Jacob S, Ruus P, Hermann R, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med.1999;27:309–14.

 

[18] Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999;22:1296–301.

 

[19] Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365–70.

 

[20] Beletate V, El Dib RP, Atallah AN. Zinc supplementation for the prevention of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005525

 

[21] Nakamura T, Higashi A, Nishiyama S, et al. Kinetics of zinc status in children with IDDM. Diabetes Care. 1991;14:553–7.

 

[22] Salway JG, Whitehead L, Finnegan JA, et al. Effect of myo-inositol on peripheral-nerve function in diabetes. Lancet. 1978 Dec 16;2(8103):1282-4.

 

 
* VCAPS and the VCAPS logo are trademarks used under license 
# This product is available in Queensland only

 <Back

11000000100000001010000011001100101010101111111110000000110000001010101010101010111100001100000010000000100010001010101011111111